In addition, genetic variants affecting PCSK9 or the respective drug target of ezetimibe, which is the cholesterol transport protein Nieman Pick C1-like 1 protein (NPC1L1P), in all cells indicated increased diabetes risk, but not in respective clinical trials, where respective drugs target PCSK9 extracellularly or indirectly cholesterol metabolism of the liver. The gene discussed is PCSK9; the disease is diabetes mellitus.